Launches July 1, 2026

Medicare Finally Covers GLP-1s in 2026

If you've been waiting years for Medicare to help with the cost of weight-loss medication, this is the moment. For the first time ever, Part D will cover them — the GLP-1 Bridge program opens July 1, 2026, bringing Wegovy and Zepbound within reach at $50 a month for those who qualify. We'll walk you through who's eligible, how to enroll, what it costs, and what happens after.

Published May 2026 · Seed data — please verify before relying on it.

Check if you qualify See Medicare-friendly programs

At a glance

The essentials, at a glance

Everything you most need to know about the Bridge program, gathered in one place.

Program name: Medicare GLP-1 Bridge Program
Start date: July 1, 2026
Patient cost: $50/month
Covered drugs: Wegovy & Zepbound
Duration: July – December 2026 (6 months)
Eligibility: Part D PDP or MA-PD enrollees
What comes next: BALANCE Model (January 2027)
Estimated eligible: ~3.4 million beneficiaries

Background

Why now, and why a 'Bridge'?

A little context helps — this is the first-ever Medicare weight-loss coverage, and it came out of a bipartisan budget deal.

For two decades, federal law actually barred Medicare from covering any drug used solely for weight loss — which is why so many people went without. The Bridge program, enabled by the TREAT Obesity Act in a budget deal signed in late 2025, finally ends that. Think of it as a six-month stepping stone (July 1 to December 31, 2026) that carries you across to the permanent BALANCE Model in 2027 — hence the name.

The figure that matters most: a $50-a-month maximum copay, against $900–$1,350 at retail. That's up to a 96% saving. And two details work quietly in your favor — the Bridge copay isn't subject to your Part D deductible, and what you spend on it doesn't count toward your 2026 Part D out-of-pocket maximum.

~3.4M

Beneficiaries eligible

The two medications you can get

Wegovy

Semaglutide 2.4mg from Novo Nordisk — a weekly injection, FDA-approved for weight management (2021) and for lowering cardiovascular risk. People lose 15–17% of their body weight on average.

Zepbound

Tirzepatide from Eli Lilly — a weekly injection, FDA-approved for weight management (2023). It works on two hunger pathways at once (GIP and GLP-1), with average weight loss of 18–22%.

What the Bridge doesn't include

Ozempic — it's covered for diabetes under standard Part D, just not through the Bridge
Mounjaro — the diabetes-labeled tirzepatide; covered for diabetes, not for weight loss
Compounded semaglutide or tirzepatide — only FDA-approved brand products make the cut
Rybelsus — the oral semaglutide pill, which carries a diabetes-only approval
Saxenda — an older, less-effective weight-loss GLP-1 that isn't part of the program

Eligibility

Do you qualify? Let's check together

It really comes down to two things: an active Part D plan and a qualifying BMI. Here's the full picture, including who isn't covered this round.

You likely qualify if…

You're enrolled in a Medicare Part D plan (a standalone PDP or an MA-PD)
Your BMI is 30 or higher — or 27+ if you have a weight-related condition
A clinician is prescribing Wegovy or Zepbound specifically for weight management
Your prescriber can document your BMI, any related conditions, and a care plan
You're able to complete a prior authorization (plans respond within 7 days)

This round may not cover you if…

You have Original Medicare (Parts A and B) but no Part D drug plan
You're a Medicaid-only enrollee without Medicare
Your BMI is below the threshold and you don't have a qualifying condition
You're hoping to use Ozempic or Mounjaro off-label for weight loss

Check if you qualify

Enrollment

Getting signed up, step by step

Here's the good part: there's no separate enrollment to wrestle with — coverage runs straight through your existing Part D plan. These are the practical steps to be ready.

Step 1

Confirm you have Part D

Pop over to Medicare.gov or call 1-800-MEDICARE. The reassuring part: the Bridge works automatically through your existing Part D plan, so there's no separate sign-up to chase down.

Step 2

Talk to your doctor

Book an in-person or telehealth visit, and bring along your BMI history and any related diagnoses. The more your prescriber has on hand, the smoother this goes.

Step 3

Get the prior authorization done

Most plans ask for one, and CMS has required a streamlined process with no step therapy — so it shouldn't be a hurdle. Aim to start it in May or June 2026 so you're ready when the program opens.

Step 4

Fill it at a network pharmacy

You'll pay $50 or less. Specialty and mail-order pharmacies count too, which is a real help if you're far from a retail counter.

Step 5

Ease into your dose

You'll start at the lowest dose and step up on the standard schedule, guided by your clinician. Going slow helps your body adjust and keeps side effects gentler.

Cost

How the Bridge stacks up against everything else

For most people on Medicare, the Bridge copay is simply the lowest sustained price available. (Manufacturer savings cards usually aren't an option for Medicare patients, because of anti-kickback rules — so this really is your best path.)

Scenario	Monthly	6-month total	Annual total
Medicare Bridge program	$50	$300	N/A (6-month program)
Commercial insurance (good)	$25–$75	$150–$450	$300–$900
Commercial insurance (typical)	$150–$300	$900–$1,800	$1,800–$3,600
Manufacturer savings card	$0–$150	$0–$900	$0–$1,800
Compounded (cash pay)	$149–$499	$894–$2,994	$1,788–$5,988
Brand-name (no insurance)	$900–$1,350	$5,400–$8,100	$10,800–$16,200

What happens after the Bridge ends

You might be wondering what comes next, and it's reassuring news. BALANCE — short for Beneficiary Access to Leveraged Anti-obesity and Nutrition Care for Equity — is a 10-year CMS Innovation Center pilot that begins January 1, 2027 and runs through 2036. It picks up right where the Bridge leaves off, with no coverage gap and no need to re-apply if you're already in the program.

The big difference: where the Bridge is a flat $50 stepping-stone benefit, BALANCE links what manufacturers charge to real outcomes — weight loss, heart events, and how consistently people stay on treatment — and pairs the medication with built-in lifestyle support. CMS expects 20+ plan sponsors and "several million" eligible beneficiaries in the first year. The exact copay structure hasn't been published yet, so we'll update this as soon as it is.

Frequently Asked Questions

Mark July 1, 2026 on your calendar — that's when the Bridge program opens, and it runs through December 31, 2026. After that, the CMS BALANCE Model picks up in January 2027, so there's no gap to worry about.

No, and that's a relief for most people. If you already have a Part D plan — whether standalone or through Medicare Advantage — coverage applies automatically. There's nothing extra to enroll in.

Yes. The Bridge covers Wegovy and Zepbound for chronic weight management, so your prescriber will document your BMI and any related condition to back up the prior authorization. It's a routine step, not a high bar.

Not at all. Your diabetes coverage continues just as it is under standard Part D. The Bridge simply adds the weight-loss drugs Wegovy and Zepbound on top — Ozempic and Mounjaro aren't part of it, so nothing you already have goes away.

You'll move automatically to the CMS BALANCE Model in January 2027 — no re-authorization, no coverage gap, nothing for you to scramble over. BALANCE is a 10-year value-based pilot that may even broaden which drugs are included down the road.

Only if you qualify for Medicare through a disability and you're enrolled in Part D. Original Medicare on its own, without a Part D plan, isn't enough for the Bridge.

Generally, yes. Medically necessary visits, including telehealth, are covered under Part B with your usual cost-sharing. Just keep in mind the $50 figure is the medication copay — it doesn't include the visit itself.

Then you won't meet the threshold for now, and we know that's disappointing to hear. Coverage requires a BMI of 30+, or 27+ with a weight-related condition like diabetes, high blood pressure, or sleep apnea. It's worth confirming your numbers with your doctor before assuming you're out.

Plans apply standard quantity limits tied to the FDA dosing schedule — usually a one-month supply per fill at your current titration dose. Nothing unusual, and your pharmacy will sort it out for you.

Yes — and that flexibility is genuinely helpful. Both are covered under the Bridge, so if one doesn't sit well with you, your clinician can move you to the other (with a fresh prior authorization where it's needed). You're not locked in.

Absolutely. Mail-order and specialty pharmacies both count under the Bridge — in fact, the program was designed with people far from a retail counter in mind, so distance shouldn't stand in your way.

It shouldn't. The Bridge is built right into the 2026 Part D framework, so it doesn't change your premium directly. As a bonus, Bridge spending doesn't count toward your 2026 Part D out-of-pocket maximum either.

Don’t want to wait until July?

You don’t have to. Affordable cash-pay GLP-1 programs start at $99 a month right now, so you can get going while you get ready for Bridge eligibility.

See the most affordable programs

2-minute match quiz

Find programs that fit the $50/mo Bridge

Answer a few quick questions and we'll give you a personalized Medicare cost estimate and a provider match in 2 minutes.

Find your match See our top programs